SSY Group Gets China Nod for Registration of Asthma, Bronchitis Drug for Bulk Preparations

MT Newswires Live
2025/11/24

SSY Group (HKG:2005) obtained production and registration approval for the Aminophylline Tablets from China's National Medical Products Administration to become a bulk drug for preparations on the market, a Monday Hong Kong bourse filing said.

The move came as the drug is regarded as passing the regulator's consistency evaluation.

The drug is mainly used to relieve wheezing symptoms in bronchial asthma, wheezing bronchitis, and obstructive emphysema, and to treat asthma caused by cardiogenic pulmonary edema.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10